Indications
Doctors use Tenecteplase in the acute phase of myocardial infarction (AMI).
⚠️ Always consult a registered physician before taking any medicine.
Pharmacology
Tenecteplase is a recombinant, fibrin-specific plasminogen activator. It is made from native t-PA by changing the protein structure at three sites. The medicine binds to the fibrin part of the thrombus (blood clot) and converts the plasminogen bound to the thrombus into plasmin, which breaks down the fibrin matrix of the clot.
Compared with native t-PA, tenecteplase has a higher fibrin specificity and resists inactivation by its natural inhibitor, PAI-1, better. It attaches to fibrin-rich clots through the fibronectin finger-like domain and the Kringle 2 domain. The protease domain then cleaves the Arg/Val bond in plasminogen to form plasmin. Plasmin in turn degrades the fibrin matrix of the thrombus, and this is how tenecteplase produces its thrombolytic action.
Pregnancy & Breastfeeding
If a woman has a myocardial infarction during pregnancy, the doctor has to weigh the benefit of treatment against the possible risks. Nobody knows whether tenecteplase passes into breast milk. Because many drugs do pass into human milk, a nursing woman should be given tenecteplase with caution.
⚠️ Talk to your doctor before taking any medicine during pregnancy or while breastfeeding.